DBVT News and Press, DBV Technologies S.A. From 10/15/21

Gainers: Jasper Therapeutics (NASDAQ:JSPR) +22%, 23andMe (NASDAQ:ME) +21%, DBV Technologies (NASDAQ:DBVT) +10%, ABVC BioPharma (NASDAQ:ABVC) +10%, Sonoma Pharmaceuticals (NASDAQ:SNOA) +8% Losers: Grove (NASDAQ:GRVI) -12%, Myomo (NYSE:MYO) -11%...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Pari...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris I...

Montrouge, France, August 31, 2021 DBV Technologies to P articipate at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that DBV Tech...

GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections an...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN ...

DBV Technologies S.A. (DBVT) Q2 2021 Earnings Conference Call August 02, 2021 05:00 PM ET Company Participants Anne Pollak - Head of Investor Relations Daniel Tassé - Chief Executive Officer Sébastien Robitaille - Chief Financial Officer Conference Call Participants Graig Suvannavej...

DBV Technologies (NASDAQ:DBVT): Q2 GAAP EPS of -$0.56 beats by $0.01. Cash and Cash Equivalents as of June 30, 2021 were $125.5 million, compared to $196.4 million as of December 31, 2020 and $152.5 million as of March 31, 2021. Press Release For further details see: DBV Technologies EP...

Montrouge, France, August 2, 2021 DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments Business Highlights : Viaskin Peanut US: DBV submitted the protocol for the 6-month adhesion and safety stu...